Information  X 
Enter a valid email address

Company Name matching 'Sanofi - Aventis Groupe'

Date
Time Source
Company
Announcement
20 May 2022 8:15 pm GNW   Sanofi - Aventis Groupe Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
15 May 2022 8:30 am GNW   Sanofi - Aventis Groupe Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy
11 May 2022 7:00 am GNW   Sanofi - Aventis Groupe Press Release: New nirsevimab data analyses reinforce efficacy against RSV
04 May 2022 11:00 am GNW   Sanofi - Aventis Groupe Press Release: Foundation S: Sanofi’s new philanthropic spearhead
03 May 2022 6:00 pm GNW   Sanofi - Aventis Groupe Press Release: Annual General Meeting of May 3, 2022
28 Apr 2022 6:30 am GNW   Sanofi - Aventis Groupe Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1
26 Apr 2022 11:47 am GNW   Sanofi - Aventis Groupe Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence
14 Apr 2022 6:00 am GNW   Sanofi - Aventis Groupe Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine
07 Apr 2022 6:00 am GNW   Sanofi - Aventis Groupe Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation
04 Apr 2022 11:00 am GNW   Sanofi - Aventis Groupe Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board
  6:00 am GNW   Sanofi - Aventis Groupe Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
01 Apr 2022 6:30 am GNW   Sanofi - Aventis Groupe Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022
31 Mar 2022 6:00 am GNW   Sanofi - Aventis Groupe Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines
30 Mar 2022 6:30 am GNW   Sanofi - Aventis Groupe Press Release: Availability of the Q1 2022 Memorandum for modelling purposes
29 Mar 2022 6:00 am GNW   Sanofi - Aventis Groupe Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets
  2:00 am GNW   Sanofi - Aventis Groupe Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver
28 Mar 2022 8:00 am GNW   Sanofi - Aventis Groupe Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency
26 Mar 2022 2:00 pm GNW   Sanofi - Aventis Groupe Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
18 Mar 2022 11:48 am GNW   Sanofi - Aventis Groupe Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris
16 Mar 2022 10:18 am GNW   Sanofi - Aventis Groupe Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
15 Mar 2022 6:00 am GNW   Sanofi - Aventis Groupe Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma
14 Mar 2022 6:00 am GNW   Sanofi - Aventis Groupe Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer
09 Mar 2022 6:00 am GNW   Sanofi - Aventis Groupe Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment
08 Mar 2022 1:25 pm GNW   Sanofi - Aventis Groupe Sanofi recognized by S&P as one of the most sustainability-committed companies
03 Mar 2022 7:00 am GNW   Sanofi - Aventis Groupe Nirsevimab significantly protected infants against RSV disease in Phase 3 trial
26 Feb 2022 5:05 pm GNW   Sanofi - Aventis Groupe Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
  5:00 pm GNW   Sanofi - Aventis Groupe Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
23 Feb 2022 10:15 am GNW   Sanofi - Aventis Groupe Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
22 Feb 2022 5:32 pm GNW   Sanofi - Aventis Groupe Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors
18 Feb 2022 6:00 am GNW   Sanofi - Aventis Groupe Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
10 Feb 2022 6:00 am GNW   Sanofi - Aventis Groupe FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
09 Feb 2022 5:00 pm GNW   Sanofi - Aventis Groupe Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD
04 Feb 2022 10:00 pm GNW   Sanofi - Aventis Groupe FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease
  6:30 am GNW   Sanofi - Aventis Groupe Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D
03 Feb 2022 4:00 pm GNW   Sanofi - Aventis Groupe Press Release: Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity
31 Jan 2022 6:00 am GNW   Sanofi - Aventis Groupe CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
19 Jan 2022 6:00 am GNW   Sanofi - Aventis Groupe Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
07 Jan 2022 6:00 am GNW   Sanofi - Aventis Groupe Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
04 Jan 2022 6:30 am GNW   Sanofi - Aventis Groupe Availability of the Q4 2021 Memorandum for modelling purposes
15 Dec 2021 6:30 am GNW   Sanofi - Aventis Groupe Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation
14 Dec 2021 2:00 pm GNW   Sanofi - Aventis Groupe Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH’s plenary and late-breaking sessions
13 Dec 2021 6:00 am GNW   Sanofi - Aventis Groupe Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session
08 Dec 2021 10:30 pm GNW   Sanofi - Aventis Groupe New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
01 Dec 2021 6:30 am GNW   Sanofi - Aventis Groupe Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates
  6:00 am GNW   Sanofi - Aventis Groupe Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy
05 Jun 2009 9:30 am PRN   Sanofi Aventis Groupe Reminder: Sanofi Aventis - Live Webcast: Breaki...
11 Feb 2009 8:45 am PRN   Sanofi Aventis Groupe Laurence Debroux Appointed Chief Strategic Offi...
  8:44 am PRN   Sanofi Aventis Groupe Jean-Pierre Lehner Appointed Chief Medical Officer
  8:32 am PRN   Sanofi Aventis Groupe Elias Zerhouni, Scientific Advisor to the Chief...


Company Announcements Archive »


a d v e r t i s e m e n t